U.S. Pate Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10540293			
	Filing Date		2005-07-20			
First Named Inventor Michael		Micha	el Ludensky			
	Art Unit		1724			
	Examiner Name P. A. I		Hruskoci			
	Attorney Docket Number		05408/100J111-US2			

		Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	3328294		1967-06-27	Self et al.	
	2	3749672		1973-31-07	Golton et al.	
	3	4297224		1981-10-27	Macchiarolo et al.	
	4	4427692		1984-01-24	Girard	
	5	4537697		1985-08-27	Grard	
	6	4698165		1987-10-06	Theyson	
	7	4925866		1990-03-15	Smith	
	8	5976386		1999-11-02	Barak	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10540293		
			2005-07-20		
			ael Ludensky		
	Art Unit		1724		
Examiner Name P. A. I		P. A.	Hruskoci		
			DE408/400 M44 LICO		

	9	6132628		2000-10	17	Barak					
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication de <sup>1</sup> Date		of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	elease click the Add	buttor	n. Add		
				FOREIG	ON PAT	TENT DOCUM	ENTS		Remove	9	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>		Country Kind Code <sup>2</sup> i Cod		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		TS
1	1	1358617	GB			1974-07-03	Alsace Mines Potasse				
2	2	96/10541	wo			1996-04-11	Weinstock David et al.				
If you wis	h to a	d additional Foreign Pa						button	=		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	9	
Examiner Initials*	Examiner Cite Initials* Cite (Dook, magazine, journal, serial, symptom) (Dook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dty ander country where published.								T5		
	1										
If you wis	ff you wish to add additional non-patent literature document citation information please click the Add button Add										

#### 

	EXAMINER SIGNATURE							
Examiner Signature		Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

18ee Kinc Ootes of USPTO Patent Documents at www.ISPTO.GOV or MPEP 901.04. I Enter office that issued the document, by the Involved (WIPO Standard S13.) "Extra office that issued the document, the Production of the Superior that precede the sear and replaced counter." I kind of document by the appropriate symbols as indicated on the document under WIPO Standard S11.6 if possible. "Applicant is to place a check mark here if English languages the instantation is attached."

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10540293		
Filing Date			2005-07-20		
	First Named Inventor Michael		ael Ludensky		
	Art Unit		1724		
	Examiner Name	P. A.	Hruskoci		
	Attorney Docket Number		05408/100J111-US2		

#### CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 QR tv	maka	the	annmonis	to co	laction/s	e١٠

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-04-12
Name/Print	Shelly M. Fuikawa	Registration Number	56190

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.